Keynote 024 042. Os was significantly improved among patients with tps 50% or more treated with pembrolizumab with 20.0 months compared with 12.2 months among patients who. Ready, md, phd, duke university medical center stephen liu, md, medstar georgetown university hospital.
However, when it is combined with. Os was significantly improved among patients with tps 50% or more treated with pembrolizumab with 20.0 months compared with 12.2 months among patients who.